Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.
Metal Implants Can Lead to Allergic Contact Dermatitis
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions
Highlights from AAD 2023